Gland Pharma Visakhapatnam facility gets USFDA EIR
Advertisement
Telangana: Gland Pharma has recently announced that the Company has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) indicating the closure of the inspection at VSEZ Sterile Oncology Facility at Visakhapatnam.
USFDA had inspected the facility between 20 th July, 2023 and 28 th July, 2023.
"This is to inform you that following the ‘Good Manufacturing Practice (GMP) Inspection’ by US FDA at the Company’s VSEZ Sterile Oncology Facility at Visakhapatnam between 20 th July, 2023 and 28 th July, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection," Gland Pharma stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.